You are here
Gates gets surprise US$87m from neglected-disease stake
[SAN FRANCISCO] The Bill & Melinda Gates Foundation received an unexpected boost to its coffers when a stake in a small biotechnology firm, made in 2013 to encourage the company's work on neglected diseases, sold for US$86.7 million - about 17 times the fund's original investment.
The windfall from the US$5 million stake in Anacor Pharmaceuticals Inc, disclosed Wednesday in a filing, highlights an atypical funding approach that the Gates Foundation, the world's largest private philanthropy, sometimes uses to spark private-sector research on conditions that mainly afflict poor people and countries, a major focus for the charity.
Non-profit foundations primarily use grants to advance their missions. While the Seattle-based Gates awards about US$4 billion annually, it has set aside a pool of about US$1.5 billion for "program-related investments," which include equity stakes, loans and other incentives for companies. The tools allow the foundation to take risks where venture capitalists would normally shy away, said Andrew Farnum, who directs the investment program.
"We're fighting with one hand behind our backs if we're only trying to do this by partnering the traditional way with the nonprofit sector," Mr Farnum said by telephone. "Some of the best technologies are found in the private sector."
Anacor, based in Palo Alto, California, makes drugs based on boron, an element with a variety of uses that has antimicrobial properties. The company has a drug approved for toenail fungus, Kerydin, and is developing a late-stage candidate treatment for atopic dermatitis, a skin condition. Gates Foundation officials who looked at the company a few years ago thought its expertise could be applied to neglected infectious diseases. Even after Anacor agreed to be taken over by drug giant Pfizer Inc this week, the work on those diseases will go on.
The Gates Foundation's deal with Anacor was struck in April, 2013 with two parts: along with the equity stake, equal to 2 per cent of the company, the charity agreed to pay the drugmaker US$17.7 million. Anacor pledged to broaden its work on treatments for tuberculosis and two parasitic diseases, river blindness and elephantiasis, and create a library of boron-based compounds targeting neglected diseases that would be accessible to other researchers and health officials through the foundation.
"Companies like the validation that comes with the Bill & Melinda Gates Foundation," Mr Farnum said. "It's a seal of approval."
It was the Gates Foundation's first investment in a publicly traded company for charitable purposes. The fund later increased its payment by US$4.4 million and extended the agreement from three years to four, while Anacor took on research into another parasitic disease, called cryptosporidiosis.
The bet began to pay off rapidly as Kerydin came to market and Anacor's shares rose. In November 2015, the charity sold all but 1 per cent of its holdings, according to the filing by the Gates Foundation. The organization didn't provide exact dates and prices for the transactions. The shares slumped from December through March, then soared Monday after Pfizer agreed to buy the company for US$5.2 billion.
The acquisition won't affect Anacor's neglected diseases work because the research agreement, which lasts until April 2017, takes into account the possibility of a sale, said Gabriella Stern, a Gates Foundation spokeswoman.
"We look forward to working with the Gates Foundation further through Anacor's agreement," Joan Campion, a Pfizer spokeswoman, said in an e-mail. A representative for Anacor declined to comment.
Drug companies ignore many diseases that are prevalent in developing nations because of the lack of financial incentives, said Peter Hotez, dean of Baylor College of Medicine's National School of Tropical Medicine in Houston, and manufacturers often have to sell products at deep discounts.
"When they go back to their shareholders and say, 'We want to invest in technologies we may have to give away,' that's a problem for the investors," he said in a telephone interview. New approaches are needed to give developing countries and their people access to innovative treatments, he said.
"Our technical ability to make products has outpaced the financial instruments and social infrastructure needed to make these innovations accessible to the poor," he said.
The proceeds from the Anacor investment will return to the foundation's pool of money for future programs, Mr Farnum said. While the stake proved to be a boon, it also shows the unpredictable nature of biotech - it could have gone the other way if Kerydin had not been approved or Anacor had poor results from other projects.
Mr Farnum says he's willing to take such chances. The charity has committed about US$1 billion to 47 investments, of which 18 are equity stakes or convertible debt. The foundation can back companies that traditional investors and venture capitalists won't touch, because it's not looking to make a return; its only motive is to do whatever it can to achieve its broader goals.
"We are going to have some great successes and frankly we'll have a larger number of failures," he said. "We have a very high appetite for risk, we think it's a competitive advantage of the foundation."